Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program.
Nikolaj FrostPetros ChristopoulosDiego Kauffmann-GuerreroJan StratmannRichard RiedelMonica SchaeferJürgen AltSylvia GützDaniel C ChristophEckart LaackMartin FaehlingRichard FischerKlaus FenchelSebastian HaenLukas HeukampChristian SchulzFrank GriesingerPublished in: Therapeutic advances in medical oncology (2021)
Our data from real-life practice demonstrate the efficacy of lorlatinib in mostly heavily pretreated patients, providing a clinically meaningful option for patients with resistance mutations not covered by other targeted therapies and those with BM or leptomeningeal carcinomatosis.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- healthcare
- quality improvement
- primary care
- prognostic factors
- dna damage
- peritoneal dialysis
- cell death
- small cell lung cancer
- electronic health record
- machine learning
- reactive oxygen species
- deep learning
- epidermal growth factor receptor